Hypothesis Acute senescence of striatal microglia releases a TGF‑β1/IGF‑1‑rich SASP that transiently up‑regulates D2 receptors on indirect‑pathway medium spiny neurons (MSNs), biasing circuit output toward goal‑directed actions and limiting maladaptive habit formation. Persistent senescence shifts the SASP toward IL‑1α/β, TNF‑α and IL‑6, driving D1 receptor up‑regulation on direct‑pathway MSNs and promoting habit rigidity.

Mechanistic Rationale

1. Temporal SASP composition – In young mice, p16INK4a‑expressing microglia that appear during remyelination show elevated TGF‑β1 and IGF‑1 secretion (see transient senescence in remyelination)[3]. These cytokines are known to enhance D2 receptor transcription via Smad3‑dependent pathways in MSNs.
2. Receptor bias – D2‑containing MSNs inhibit the indirect pathway, reducing thalamic excitatory drive and favoring action selection over habitual routines. Conversely, chronic senescent microglia secrete classic pro‑inflammatory SASP components that activate NF‑κB in MSNs, increasing D1 receptor expression and strengthening the direct pathway, which encodes stimulus‑response habits.
3. Circuit outcome – A temporary D2‑dominant state stabilizes flexible behavior; a shift to D1 dominance locks the dorsal striatum into rigid, habit‑like output, mirroring the progression from early‑stage Parkinson’s motor flexibility to later‑stage bradykinesia and compulsivity.

Testable Predictions

• Prediction 1: Genetic ablation of p16INK4a‑positive microglia at 2 months (early transient window) will reduce TGF‑β1/IGF‑1 levels in striatal extracellular fluid, lower D2 receptor mRNA in indirect‑pathway MSNs, and increase habit‑biased performance on a sequential decision task.
• Prediction 2: Inducing senescence at 12 months (chronic window) will elevate IL‑1α/β, TNF‑α, IL‑6, raise D1 receptor expression, and exacerbate habit formation while impairing goal‑directed learning.
• Prediction 3: Pharmacological neutralization of TGF‑β1 or IGF‑1 during the early window will phenocopy the genetic ablation effects, whereas blockade of IL‑1 signaling in aged mice will rescue D2 expression and improve cognitive flexibility.

Experimental Approach

• Model: Use Cx3cr1‑CreER; p16‑3MR mice to allow tamoxifen‑inducible, microglia‑specific senescence induction or apoptosis.
• Groups: (i) Young (2 mo) senescence induction, (ii) Young senescence induction + anti‑TGF‑β1/IGF‑1 antibodies, (iii) Aged (12 mo) senescence induction, (iv) Aged senescence induction + IL‑1Ra antagonist.
• Readouts:
  • ELISA of striatal interstitial fluid for TGF‑β1, IGF‑1, IL‑1α/β, TNF‑α, IL‑6 (samples from microdialysis).
  • qPCR and RNAscope for Drd1 and Drd2 in DARPP‑32+ and Enk+ MSNs isolated by FACS.
  • In vivo two‑photon calcium imaging of MSN activity during a touchscreen‑based sequential choice task that dissociates goal‑directed from habit performance.
  • Behavioral metrics: sensitivity to outcome devaluation (goal‑directed) vs. resistance to devaluation (habit).
• Analysis: Two‑way ANOVA (age × intervention) with post‑hoc tests; significance set at p<0.05. Effect sizes reported as Cohen’s d.

Falsification If acute microglial senescence fails to alter TGF‑β1/IGF‑1 levels, does not change D2 receptor expression, or does not shift behavior toward goal‑directed control, the hypothesis is refuted. Likewise, if chronic senescence does not increase pro‑inflammatory cytokines or D1 receptor expression, the proposed SASP switch lacks mechanistic basis.

Broader Impact This framework re‑positions senescence as a dynamic tuner of basal ganglia signaling rather than a static toxin. It suggests that timing‑specific senolytics or SASP modulation could preserve cognitive flexibility in aging and early Parkinson’s disease, aligning with recent calls to contextualize senescent cell function[1][2][4][5][6][7].